T 0099/13 () of 14.1.2016

European Case Law Identifier: ECLI:EP:BA:2016:T009913.20160114
Date of decision: 14 January 2016
Case number: T 0099/13
Application number: 01981824.4
IPC class: A61K 47/02
A61K 47/12
A61K 47/18
A61K 39/395
Language of proceedings: EN
Distribution: C
Download and more information:
Decision text in EN (PDF, 415 KB)
Documentation of the appeal procedure can be found in the Register
Bibliographic information is available in: EN
Versions: Unpublished
Title of application: REDUCED-VISCOSITY CONCENTRATED PROTEIN FORMULATIONS
Applicant name: Genentech, Inc.
Novartis AG
Opponent name: Arecor Limited
UCB PHARMA S.A.
Ablynx N.V.
SANOFI
Boehringer Ingelheim Pharma GmbH & Co. KG/
Boehringer Ingelheim International GmbH
Octapharma AG
Dr. Martin Huenges/, Dr. Lüder Behrens
Baxter Healthcare S.A.
AbbVie Bioresearch Center Inc.
Synthon B.V.
Board: 3.3.07
Headnote: -
Relevant legal provisions:
European Patent Convention Art 111(1)
European Patent Convention Art 123(2)
European Patent Convention R 101(1)
Keywords: Admissibility of appeal - appeal sufficiently substantiated (yes)
Amendments - added subject-matter (no)
Appeal decision - remittal to the department of first instance (yes)
Catchwords:

see point 2.3

Cited decisions:
T 1269/06
T 0667/08
Citing decisions:
T 2255/12
T 1867/16
T 2282/17
T 0363/18
T 1173/18

Source: http://www.epo.org/law-practice/case-law-appeals/recent/t130099eu1.html

Date retrieved: 17 May 2021

10 references found.

Click X to load a reference inside the current page, click on the title to open in a new page.

EPC Articles

EPC Implementing Rules

EPO Guidelines - H Amendments and Corrections

Offical Journal of the EPO

Case Law Book: II Conditions to be met by an Application

General Case Law